Gilead Sciences (GILD) 78.49 $GILD
Beyond Bristol's Big Dividend: 3 Things Investors Need to Know
Todd Campbell, The Motley Fool - Motley Fool - Wed Apr 30, 5:30PM CDT
Bristol-Myers ' first-quarter sales appear tepid at best as revenue fell 1% to $3.8 billion, although its juicy dividend of 2.9% has certainly been attractive to income investors.However, there are some encouraging signs that Bristol may be...
Final Glance: Biotechnology companies
AP - Wed Apr 30, 5:07PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Gilead Sciences Rises 2.95% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Apr 30, 3:40PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $75.49 to a high of $78.67. Yesterday, the shares gained 3.0%, which took the trading range above the 3-day high of $76.80 on volume of 20.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
After Yesterday's Rally of 2.95% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Apr 30, 3:40PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $75.49 to a high of $78.67. Yesterday, the shares gained 3.0%, which took the trading range above the 3-day high of $76.80 on volume of 20.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Amicus Up on Positive Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 1:32PM CDT
Shares of Amicus Therapeutics (FOLD) shot up 20.7% after it announced positive data from its first phase III study on migalastat HCl monotherapy.
Earnings Roundup: Is AbbVie on Borrowed Time?
Todd Campbell, The Motley Fool - Motley Fool - Wed Apr 30, 1:30PM CDT
AbbVie 's better-than-hoped first-quarter earnings has shares rallying since mid-month. However, shares remain down on the year on concerns that its new hepatitis C drug won't live up to expectations and be able to blunt the eventual risk of patent...
Midday Glance: Biotechnology companies
AP - Wed Apr 30, 1:12PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Jim Cramer: Spend Is a Four-Letter Word
at The Street - Wed Apr 30, 10:26AM CDT
The market wants companies that are taking share with minimal spending.
Biotech Stock Roundup: Gilead's Sovaldi Shines, Biogen & Alexion Up Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 30, 9:55AM CDT
Gilead's (GILD) Sovaldi remained in the limelight with sales blowing past expectations.
Early Glance: Biotechnology companies
AP - Wed Apr 30, 9:46AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 10 a.m.:
Here's What This $19 Billion Hedge Fund Is Buying
Selena Maranjian, The Motley Fool - Motley Fool - Wed Apr 30, 9:26AM CDT
Every quarter, many money managers have to disclose what they've bought and sold via "13F" filings. Their latest moves can shine a bright light on smart stock picks. Today, let's look at Acadian Asset Management, begun in 1988 as a foreign stock...
Stock Market News for April 30, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 9:06AM CDT
Upbeat earnings results and gains in high-growth stocks helped benchmarks close in the green on Tuesday
Parion Sciences Reacquires Rights to Epithelial Sodium Channel Inhibitors
PR Newswire - Wed Apr 30, 8:00AM CDT
Parion Sciences, a company dedicated to the development of novel treatments for pulmonary and ocular diseases, announced today that it has reached an agreement with Gilead Sciences, Inc. to reacquire the rights to epithelial sodium channel (ENaC) inhibitors identified and developed under a research collaboration announced between the parties in 2007. Gilead is eligible to receive future undisclosed royalties based upon the commercial success of select compounds.
Q2 Earnings Estimates Coming Down - Earnings Trends
Sheraz Mian - Zacks Investment Research - Wed Apr 30, 2:10AM CDT
Q2 Earnings Estimates Coming Down - Earnings Trends
Q2 Earnings Estimates Coming Down - Earnings Outlook
Sheraz Mian - Zacks Investment Research - Wed Apr 30, 2:10AM CDT
Q2 Earnings Estimates Coming Down - Earnings Outlook
Intercept Pharmaceuticals: What Investors Need to Watch
Brian Nichols, The Motley Fool - Motley Fool - Tue Apr 29, 5:30PM CDT
After soaring on positive clinical trial news in January, shares of Intercept Pharmaceuticals have fallen 50% from their highs. The biotech, which currently sports a market cap of $5.5 billion, jumped following positive data from its drug...
Key Takeaways From Gilead Sciences' First Quarter
Cory Renauer, The Motley Fool - Motley Fool - Tue Apr 29, 5:30PM CDT
Last week, Gilead Sciences revealed first quarter results that took analysts by surprise. Earnings per share of $1.33 came in almost 50% above the average estimate of $0.89. Total revenue of $5 billion was 27.6% above the average estimate of $3.92...
Will These 3 Drugs Keep AbbVie's Future Bright After Humira?
Dan Carroll, The Motley Fool - Motley Fool - Tue Apr 29, 5:30PM CDT
AbbVie has struggled to keep up with its industry peers this year. The stock's down double-digit percentages in 2014 despite strong sales growth from top drug Humira, the immunology therapy that made up around 58% of AbbVie's total revenue in its...
OncoGenex's Custirsen Misses Primary Endpoint - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 5:29PM CDT
Shares of OncoGenex (OGXI) tumbled 60.3% after it announced that its lead candidate, custirsen, failed to meet its primary endpoint in the phase III, SYNERGY study.
Can Affymetrix (AFFX) Surprise This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 5:25PM CDT
Affymetrix (AFFX) had delivered positive earnings surprises in 2 of its last 4 quarters, with an impressive average beat of 192.86%.
Beyond Bristol's Big Dividend: 3 Things Investors Need to Know
Todd Campbell, The Motley Fool - Motley Fool - Wed Apr 30, 5:30PM CDT
Bristol-Myers ' first-quarter sales appear tepid at best as revenue fell 1% to $3.8 billion, although its juicy dividend of 2.9% has certainly been attractive to income investors.However, there are some encouraging signs that Bristol may be...
Final Glance: Biotechnology companies
AP - Wed Apr 30, 5:07PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Gilead Sciences Rises 2.95% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Apr 30, 3:40PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $75.49 to a high of $78.67. Yesterday, the shares gained 3.0%, which took the trading range above the 3-day high of $76.80 on volume of 20.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
After Yesterday's Rally of 2.95% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Apr 30, 3:40PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $75.49 to a high of $78.67. Yesterday, the shares gained 3.0%, which took the trading range above the 3-day high of $76.80 on volume of 20.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Amicus Up on Positive Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 1:32PM CDT
Shares of Amicus Therapeutics (FOLD) shot up 20.7% after it announced positive data from its first phase III study on migalastat HCl monotherapy.
Earnings Roundup: Is AbbVie on Borrowed Time?
Todd Campbell, The Motley Fool - Motley Fool - Wed Apr 30, 1:30PM CDT
AbbVie 's better-than-hoped first-quarter earnings has shares rallying since mid-month. However, shares remain down on the year on concerns that its new hepatitis C drug won't live up to expectations and be able to blunt the eventual risk of patent...
Midday Glance: Biotechnology companies
AP - Wed Apr 30, 1:12PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Jim Cramer: Spend Is a Four-Letter Word
at The Street - Wed Apr 30, 10:26AM CDT
The market wants companies that are taking share with minimal spending.
Biotech Stock Roundup: Gilead's Sovaldi Shines, Biogen & Alexion Up Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 30, 9:55AM CDT
Gilead's (GILD) Sovaldi remained in the limelight with sales blowing past expectations.
Early Glance: Biotechnology companies
AP - Wed Apr 30, 9:46AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 10 a.m.:
Here's What This $19 Billion Hedge Fund Is Buying
Selena Maranjian, The Motley Fool - Motley Fool - Wed Apr 30, 9:26AM CDT
Every quarter, many money managers have to disclose what they've bought and sold via "13F" filings. Their latest moves can shine a bright light on smart stock picks. Today, let's look at Acadian Asset Management, begun in 1988 as a foreign stock...
Stock Market News for April 30, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 9:06AM CDT
Upbeat earnings results and gains in high-growth stocks helped benchmarks close in the green on Tuesday
Parion Sciences Reacquires Rights to Epithelial Sodium Channel Inhibitors
PR Newswire - Wed Apr 30, 8:00AM CDT
Parion Sciences, a company dedicated to the development of novel treatments for pulmonary and ocular diseases, announced today that it has reached an agreement with Gilead Sciences, Inc. to reacquire the rights to epithelial sodium channel (ENaC) inhibitors identified and developed under a research collaboration announced between the parties in 2007. Gilead is eligible to receive future undisclosed royalties based upon the commercial success of select compounds.
Q2 Earnings Estimates Coming Down - Earnings Trends
Sheraz Mian - Zacks Investment Research - Wed Apr 30, 2:10AM CDT
Q2 Earnings Estimates Coming Down - Earnings Trends
Q2 Earnings Estimates Coming Down - Earnings Outlook
Sheraz Mian - Zacks Investment Research - Wed Apr 30, 2:10AM CDT
Q2 Earnings Estimates Coming Down - Earnings Outlook
Intercept Pharmaceuticals: What Investors Need to Watch
Brian Nichols, The Motley Fool - Motley Fool - Tue Apr 29, 5:30PM CDT
After soaring on positive clinical trial news in January, shares of Intercept Pharmaceuticals have fallen 50% from their highs. The biotech, which currently sports a market cap of $5.5 billion, jumped following positive data from its drug...
Key Takeaways From Gilead Sciences' First Quarter
Cory Renauer, The Motley Fool - Motley Fool - Tue Apr 29, 5:30PM CDT
Last week, Gilead Sciences revealed first quarter results that took analysts by surprise. Earnings per share of $1.33 came in almost 50% above the average estimate of $0.89. Total revenue of $5 billion was 27.6% above the average estimate of $3.92...
Will These 3 Drugs Keep AbbVie's Future Bright After Humira?
Dan Carroll, The Motley Fool - Motley Fool - Tue Apr 29, 5:30PM CDT
AbbVie has struggled to keep up with its industry peers this year. The stock's down double-digit percentages in 2014 despite strong sales growth from top drug Humira, the immunology therapy that made up around 58% of AbbVie's total revenue in its...
OncoGenex's Custirsen Misses Primary Endpoint - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 5:29PM CDT
Shares of OncoGenex (OGXI) tumbled 60.3% after it announced that its lead candidate, custirsen, failed to meet its primary endpoint in the phase III, SYNERGY study.
Can Affymetrix (AFFX) Surprise This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 5:25PM CDT
Affymetrix (AFFX) had delivered positive earnings surprises in 2 of its last 4 quarters, with an impressive average beat of 192.86%.
